Imugene (AU:IMU)
ASX:IMU
Want to see AU:IMU full AI Analyst Report?
IMU Stock Chart & Stats
AU$0.33
>-AU$0.01(-2.22%)
At close: 4:00 PM EST
AU$0.33
>-AU$0.01(-2.22%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.54
Previous CloseN/A
Volume11.90M
Average Volume (3M)877.83K
Market Cap
AU$37.84M
Enterprise ValueAU$38.71M
Total Cash (Recent Filing)AU$14.14M
Total Debt (Recent Filing)AU$5.02M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Sep 02, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding415,835,050
10 Day Avg. Volume850,615
30 Day Avg. Volume877,834
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside-24.24% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.14
Revenue Forecast (FY)AU$5.00M
Bulls Say, Bears Say
Bulls Say
Diversified R&D PipelineImugene pursues multiple immuno-oncology modalities (oncolytic viruses, B‑cell activators, CAR T and engagers). This multi‑asset approach reduces binary outcome risk for the company, increases pathways to partnerships or licensing, and raises the odds of a value-inflecting clinical success over time.
Low Financial LeverageA debt-to-equity of 0.24 and moderate equity ratio signal conservative leverage. Lower fixed obligations provide balance sheet flexibility to fund extended clinical programs, pursue collaborations, and withstand lengthy development timelines without near-term solvency pressure compared with highly levered peers.
High Reported Gross MarginA 100% gross margin (as reported) implies favorable per-product economics if Imugene achieves commercialization or receives milestone/licensing revenue. Structurally, high gross margins support healthy long‑term profitability potential once fixed R&D and SG&A are covered by sustainable revenues or partner arrangements.
Bears Say
Severe Revenue ContractionA ~-339% revenue change reflects effectively no recurring product sales and volatile or one-off revenue recognition. This structural lack of commercial revenue leaves Imugene reliant on capital markets or deals, reducing predictability of cash flow and increasing execution and dilution risk over the medium term.
Persistent Negative Operating Cash FlowNegative operating cash flow shows the company is burning cash to fund R&D and operations. Absent product revenues or material partner receipts, recurring cash burn pressures reserves and forces capital raises or licensing, which can dilute shareholders and limit long‑term strategic flexibility.
Deeply Negative Profitability And ROENegative net margin and very poor ROE demonstrate the company is not producing returns on its equity base. Structurally, prolonged unprofitability undermines the ability to self‑fund development, increases dependency on external capital, and heightens the importance of timely clinical or partnership milestones to restore sustainable economics.
Imugene News
IMU FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest share price was AU$0.09 and its highest was AU$0.54 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is AU$37.84M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Sep 02, 2026 which is in 81 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Feb 25, 2026. The company reported -AU$0.13 earnings per share for the quarter, beating the consensus estimate of -AU$0.34 by AU$0.21.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Overvalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate is -0.04.
How many shares outstanding does Imugene have?
Imugene has 415,835,050 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -AU$0.13 in its last earnings report, beating expectations of -AU$0.34. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in AU:IMU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.25 (-24.24% Downside)
AU$0.25 (-24.24% Downside)
Blogger Sentiment
Neutral
AU:IMU Sentiment 59%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$89.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.71%
12-Months-Change
Fundamentals
Return on Equity
-134.65%
Trailing 12-Months
Asset Growth
-39.73%
Trailing 12-Months
Company Description
Imugene
Imugene Limited is an Australian clinical-stage immuno-oncology firm focused on creating innovative immunotherapies. Its core mission is to activate the immune systems of cancer patients, enabling them to effectively fight and eradicate tumors. A primary asset in their development pipeline is HER-Vaxx, a vaccine tailored for HER2-positive cancers. This therapy works by stimulating the body to generate a diverse antibody response against HER2/neu receptors, specifically targeting gastric and breast cancers. HER-Vaxx is currently progressing through Phase 1b/2 clinical studies for gastric cancer indications. Beyond HER-Vaxx, the company is also developing PD1-Vaxx, another cancer vaccine designed to prompt the body to produce antibodies that block PD-1 signaling. Additionally, they are advancing CF33, which combines genomic material from various vaccinia virus strains to engineer a highly potent virus. Imugene has established key partnerships, including a research collaboration with Celularity Inc. to integrate Imugene's CD19 oncolytic virus technology with Celularity's CD19-targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19, for solid tumor treatment. The company also maintains a strategic collaboration with Eureka Therapeutics, Inc. Founded in 1986, Imugene Limited is headquartered in Sydney, Australia.
IMU Stock 12 Month Forecast
Average Price Target
AU$0.25
▼(-24.24% Downside)
Technical Analysis
Immutep Ltd
―
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Noxopharm Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---